Scarica l'app Stockscreener
3.1103
17.64%
0.5303
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.58
Aprire:
$3.19
Volume 24 ore:
58.04M
Relative Volume:
18.75
Capitalizzazione di mercato:
$18.06M
Reddito:
-
Utile/perdita netta:
$-16.76M
Rapporto P/E:
-38.88
EPS:
-0.08
Flusso di cassa netto:
$-132.97M
1 W Prestazione:
+92.09%
1M Prestazione:
+112.24%
6M Prestazione:
-79.87%
1 anno Prestazione:
-83.28%
Intervallo 1D:
$2.83
$3.45
Intervallo di 1 settimana:
$1.35
$3.45
Portata 52W:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Nome
X 4 Pharmaceuticals Inc
Settore
Industria
Telefono
857-529-8300
Indirizzo
61 NORTH BEACON STREET, BOSTON, MA
Confronta XFOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.12 | 10.19M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.69 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.12 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.10 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
639.00 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.96 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-12 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Ripresa | B. Riley Securities | Buy |
| 2022-12-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | ROTH Capital | Buy |
| 2019-12-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-12-05 | Iniziato | B. Riley FBR | Buy |
| 2019-06-07 | Iniziato | Stifel | Buy |
| 2019-06-05 | Iniziato | Cowen | Outperform |
Mostra tutto
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
X4 Pharmaceuticals Expands Private Placement to $85M for Rare Disease Drug Development - Stock Titan
Using Bollinger Bands to evaluate X4 Pharmaceuticals Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
Reversal indicators forming on X4 Pharmaceuticals Inc. stockJuly 2025 Sentiment & Safe Entry Point Alerts - Newser
Why X4 Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Market Mood & AI Powered Market Entry Strategies - Newser
Will X4 Pharmaceuticals Inc. benefit from macro trends [Weekly Investment Recap]Fast Entry Momentum Trade Alerts - Newser
X4 Pharmaceuticals Inc.’s volatility index tracking explained [Weekly Trend Recap]Technical Pattern Based Buy Signals - Newser
Real time alert setup for X4 Pharmaceuticals Inc. performanceFree Reliable Investment Entry Point Signals - Newser
XFOR’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
XFOR Stock Skyrockets: Buy Now? - StocksToTrade
X4 Pharmaceuticals Announces $60 Million Equity Financing - citybiz
XFOR’s Unexpected Surge: What’s Driving the Price? - timothysykes.com
X4 Pharma Secures $60 Mln PIPE Financing; CEO, CFO Resign; Replacements Named - Nasdaq
X4 Pharmaceuticals Inc. stock outlook for YEARCapital Secure Pattern Signal Analysis Sheet - Newser
X4 Pharmaceuticals secures $60 million in financing, appoints new leadership - Investing.com
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors - simplywall.st
X4 Pharmaceuticals Overhauls Leadership: $60M Deal Brings CTI BioPharma's $1.7B Exit Team Onboard - Stock Titan
X4 Pharmaceuticals Inc.’s volatility index tracking explainedFree Oversold Bounce Stock Play Ideas - Newser
Will X4 Pharmaceuticals Inc. benefit from macro trendsPattern Breakout Prediction for Short Term - Newser
Regression analysis insights on X4 Pharmaceuticals Inc. performanceFree Daily Top Performing Stock Insights - Newser
How X4 Pharmaceuticals Inc. stock performs during market volatilityTechnical Trend Forecast for Investors - Newser
How to use Fibonacci retracement on X4 Pharmaceuticals Inc.Low Risk Trade Timing with Analysis Metrics - Newser
Exit strategy if you’re trapped in X4 Pharmaceuticals Inc.Smart Safety Strategy With Real Data Analysis - Newser
Momentum divergence signals in X4 Pharmaceuticals Inc. chartIn-Depth Stock Trading Volume Analysis - Newser
How to integrate X4 Pharmaceuticals Inc. into portfolio analysis toolsFree Fast Entry High Potential Stock Alerts - Newser
2 Outperform Rated Small Caps with Recent Pull-backs - TradingView
Combining price and volume data for X4 Pharmaceuticals Inc.Secure Buy Strategy Based on Risk Parameters - Newser
X4 Pharmaceuticals Inc. stock daily chart insightsAI-Powered Stock Trend Movement Analysis - Newser
Leading vs lagging indicators on X4 Pharmaceuticals Inc. performanceEntry Zone Forecast for Momentum Trading - Newser
Is X4 Pharmaceuticals Inc. building a consolidation baseBreakout Watcher with Entry and Exit Alerts - Newser
What analysts say about X4 Pharmaceuticals Inc. stock outlookPredictable Return Plan with Entry Guidance - Newser
Does X4 Pharmaceuticals Inc. fit your quant trading modelBuy Candidate Summary Based on Fundamentals - Newser
X4 Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X4 Pharmaceuticals, Inc SEC 10-Q Report - TradingView
Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech
X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday - Defense World
What makes X4 Pharmaceuticals Inc. stock price move sharplyLong-Term Stock Growth Forecast Insights - Newser
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
X 4 Pharmaceuticals Inc Azioni (XFOR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.45%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):